A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
Public ClinicalTrials.gov record NCT04736628. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function. Three different doses of avenciguat are tested in this study. Participants get either one of the three doses of avenciguat or placebo. It is decided by chance who gets which avenciguat dose and who gets placebo. Participants take avenciguat or placebo as tablets 3 times a day. Placebo tablets look like avenciguat tablets but do not contain any medicine. Participants continue taking their usual medicine for kidney disease throughout the study. Participants are in the study for about 7 months. During this time, they visit the study site about 11 times. Where possible, about 6 of the 11 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Kidney function is assessed based on the analysis of urine samples, which participants collect at home. At the end of the trial the results are compared between the different doses of avenciguat and placebo. During the study, the doctors also regularly check the general health of the participants.
Study identification
- NCT ID
- NCT04736628
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 261 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2021
- Primary completion
- Aug 14, 2023
- Completion
- Sep 20, 2023
- Last update posted
- Sep 3, 2024
2021 – 2023
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Medical Research, LLC | Canyon Country | California | 91351 | — |
| Rancho Cucamonga Clinical Trials | Rancho Cucamonga | California | 91730 | — |
| Kidney & Hypertension Center | Victorville | California | 92395 | — |
| Chase Medical Research, LLC | Waterbury | Connecticut | 06708 | — |
| Nephrology Associates, P.A. | Newark | Delaware | 19713 | — |
| Indago Research and Health Center | Hialeah | Florida | 33012 | — |
| Homestead Associates in Research | Miami | Florida | 33032 | — |
| Bioclinical Research Alliance, Inc. | Miami | Florida | 33155 | — |
| Alma Clinical Research, Inc. | Miami | Florida | 33165 | — |
| Panax Clinical Research | Miami Lakes | Florida | 33014 | — |
| Davita Clinical Research | Columbus | Georgia | 31904 | — |
| Meridian Clinical Research, LLC | Savannah | Georgia | 31406 | — |
| Boise Kidney and Hypertension, PLLC | Boise | Idaho | 83706 | — |
| Research by Design, LLC | Chicago | Illinois | 60643 | — |
| Renal Associates of Baton Rouge | Baton Rouge | Louisiana | 70808 | — |
| DaVita Clinical Research | Las Vegas | Nevada | 89128 | — |
| Nevada Kidney Disease and Hypertension Centers, PLLC | Las Vegas | Nevada | 89128 | — |
| New Jersey Kidney Care, LLC | Jersey City | New Jersey | 07305 | — |
| Brookview Hills Research Associates LLC | Winston-Salem | North Carolina | 27103 | — |
| Knoxville Kidney Center PLLC | Knoxville | Tennessee | 37923 | — |
| Davita Clinical Research | El Paso | Texas | 79925 | — |
| Clinical Advancement Center, PLLC | San Antonio | Texas | 78212 | — |
| Kidney Specialists of North Houston, PLLC | Shenandoah | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04736628, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04736628 live on ClinicalTrials.gov.